Basiliximab Articles
SangStat transplant trial halted early
18 March 2002
Novartis gets CPMP OK for pediatric Simulect
23 August 2000
Ligand sells Marathon assets for $10 million
11 January 2000
Cash boost for Ligand as Elan raises stake
4 January 2000
Roche's Zenapax approved by the European Commission
4 March 1999
Novartis 1998 sales down on forecasts
21 January 1999
Basiliximab Launched In The UK
8 December 1998
Pharma Sales Give Novartis Boost
22 October 1998
EU Approval For Novartis' Simulect
16 October 1998
Novartis Restructures After Disappointing First Half
1 September 1998
Novartis First Half Sales Under Expectations
16 July 1998
Novartis' Simulect Gets CPMP Backing
30 June 1998
Stock Commentary New York
18 June 1998
Stock Commentary Europe
28 May 1998
LeukoSite Lead Product May Be On Market By 2000
28 May 1998
Novartis' Exelon Cleared In First Major Market
14 May 1998
Ligand Announces Lilly, Seragen & Marathon Deals
12 May 1998
Novartis Granted First Approval For Simulect
16 April 1998
Roche's Zenapax Gets First Approval For Transplants
17 December 1997
Celltech Reflects On Pipeline After Mixed Fortunes In '97
16 December 1997
Novartis Files BLA For Simulect
20 November 1997
Phase III Results With Novartis' Basiliximab
29 October 1997
Novartis Unveils Strong Product Pipeline
1 July 1997
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Showing 1-32 of 32 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
